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Abstract
Introduction: The incidence of postoperative thrombocytopenia 
after aortic valve replacement (AVR) with the Perceval S 
Sutureless bioprosthesis remains unclear. The aim of this study 
was to report thrombocytopenia associated with the use of 
sutureless AVR. 
Methods: The data was collected retrospectively for patients 
who had isolated AVR with sutureless Perceval S valve (Group A: 
72 patients) and was compared with patients who underwent 
isolated sutured AVR with Perimount Magna Ease Bioprosthesis 
(Group B: 101 patients) in our institution between June 2014 and 
January 2017. 
Results: Cardiopulmonary bypass and cross-clamp time were 
significantly shorter in group A. Maximum drop in platelet count 
was 58% mean (day 2.3) in group A versus 44% mean (day 1.7) 
in group B (P=0.0001). Absolute platelet count on postoperative 
day 1-6 in group A was significantly less than in group B (P≤0.05). 
Platelet count recovered to preoperative value in 44% patients 
in group B versus only in 26% patients in group A at discharge 
(P=0.018). Moderate thrombocytopenia occurs more often in 
group A (41% vs. 26%) (P=0.008) while severe thrombocytopenia 
(<50 x 109) was observed in 6% in group A but never in group 
B. Platelets (P=0.007) and packed red blood cells (P=0.009) 
transfusion was significantly higher in the group A. 
Conclusion: The implantation of sutureless Perceval aortic 
valves was associated with a significant drop in platelet count 
postoperatively with slow recovery and higher platelets and 
packed red blood cells transfusion requirements. A prospective 
randomised trial is needed to confirm our findings.  
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Abbreviations, acronyms & symbols
AVR
CPB
ECC
POD
TAVI
 = Aortic valve replacement 
 = Cardiopulmonary bypass
 = Extracorporeal circulation 
 = Postoperative day 
 = Transcatheter aortic valve implantation 
INTRODUCTION
Surgical aortic valve replacement (AVR) still represents the 
gold standard in patients with severe aortic valve stenosis[1]. 
Owing to increasing age of the patient population in the 
Western world, there has been an increase in the prevalence 
of patients with valvular heart disease eligible for AVR[2]. Given 
the increasing number of co-morbidities and the increasing 
age of patients, a tendency has emerged to use biological valve 
implants thus avoiding the need for long-term anticoagulation 
therapy. Although the concept of transcatheter aortic valve 
implantation (TAVI) appears attractive, the calcified aortic valve 
is not removed during this procedure. Therefore, paravalvular 
leakage remains an important issue with this technique[3]. Other 
important concerns are access site-related problems and device 
malpositioning.
The recent introduction of sutureless bioprostheses may 
offer an additional tool in the therapeutic armamentarium as 
these valves do not need to be sutured into place resulting 
in shorter cross-clamp and cardiopulmonary bypass (CPB) 
durations which may be beneficial in older patients with co-
morbid conditions. Moreover, due to the absence of a sewing 
ring, these valves exhibit favourable hemodynamic properties. 
Excellent outcomes have been demonstrated with sutureless 
AVR in minimally invasive surgical setting[4].
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was collapsed in a side table and placed into the manufacturer’s 
holder. The three guiding sutures were passed through the three 
green holes arising from the annular ring of the prosthesis, which 
was consequently seated on the debrided annulus. Once the 
delivery system is in position, the stent is deployed by turning the 
release screw and leaving the valve in place. The delivery system 
and the guiding sutures are removed. The field was rinsed with 
warm saline, and the prosthesis was dilated at four atmospheres 
for 30 seconds. 
On first postoperative day, patients were started on aspirin 
150 mg orally and low molecular weight heparin subcutaneously 
for deep vein thrombosis prophylaxis.  
Statistical Analysis
All data has been extracted from the Dendrite PATS CS2010F 
SCTS v4.1.2 database. Date of data extract was 25.07.17 to cover 
the period from 01.06.2014 to 31.01.17. Analysis was performed 
using MS Excel. Numerical values were compared using an 
independent t-Test, with a two-tailed distribution assuming 
unequal variances. Categorical variables were compared using 
Chi Square χ2 analysis.
RESULTS
The preoperative characteristics of patients are depicted in 
Tables 1 and 2. There was no difference between Group A and B 
regarding history of preoperative renal impairment or pulmonary 
disease. Group A has more female patients (A=52% vs. B=31%; 
P≤0.004), patients with hypertension (79% vs. 60%; P=0.01), 
neurological dysfunction (17% vs. 7%; P=0.05) and angina (54% 
vs. 37%; P=0.03). In group A, patients were older (range: 54-84, 
mean 74 vs. 47-86, mean 70 vs. range 34-91, mean 71; P=0.001) 
and with higher logistic EuroSCORE (3.07 vs. 1.87; P=0.001). 
Greater number of L and XL size valves was implanted 
in Perceval valve group, and of 23 and 25 mm prosthesis in 
Perimount Magna Ease group (Table 3).
When Perceval valve sizes S, M, L and XL were compared 
with their counterpart Perimount Magna Ease valve sizes, there 
was more significant thrombocytopenia in Perceval group 
(Table 4). Haematology data is depicted in Tables 5, 6 and 7. 
Among the Perceval valve group, 5 (6%) patients had severe 
thrombocytopenia. Their peak reduction was on day 3 with 58% 
of their preoperative platelet value. While in Perimount Magna 
group none of them had severe thrombocytopenia. Their peak 
reduction was on day 2 with 44% of preoperative value which is 
significantly less then Perceval valve group. Perceval valve group 
required more blood (1.5 vs. 0.7 units) (P=0.009) and platelet 
(0.3 vs. 0.1 platelets pools; P=0.007) transfusion. No significant 
difference in absolute platelet count between two groups on 
preoperative and operation days was observed. Platelet count 
was significantly reduced in Perceval group from day 1-6 and 
20% patients came back to preoperative level at discharge. Forty-
four percent of Perimount patients came back to preoperative 
value at the time of discharge. Forty-one percent of Perimount 
group had moderate thrombocytopenia while this value was 
26% in Perceval valve group.
We noticed that sutureless valves are associated with greater 
drops in postoperative platelet counts compared to sutured 
valves. Albacker[5] reported this phenomenon with sutureless 
AVR and the aim of this study was to investigate this observation 
and try to find an explanation for its occurrence.
METHODS 
Patients
It is a retrospective, observational study. All the patients 
who underwent isolated sutureless Perceval AVR between June 
2014 and November 2016 were compared with patients who 
had isolated AVR with Carpentier-Edwards Perimount Magna 
Ease valve between June 2015 and January 2017. Any non-
isolated AVR cases i.e.: coronary artery bypass grafting, mitral and 
tricuspid valve surgery, myomectomy, ascending aorta surgery 
were excluded. Moreover, all the redo, emergency and infective 
endocarditis patients were excluded. 
All the sutureless AVRs were performed by the six different 
surgeons in our institution during that period. Data was collected on 
all the patients who underwent sutured AVR by the same surgeons 
during the same time period (101 patients) as a control group.
A total of 72 patients received isolated Perceval bioprosthesis 
and 101 patients had Perimount Magna Ease valve. The Percevel 
S valve sizes were small, medium, large and extra-large. For 
statistical purposes they were taken as equivalent to 19-21, 23, 
25 and 27 mm Perimount Magna Ease sizes, respectively.
Severe thrombocytopenia was defined as a platelet count 
<50x109/Lit during the postoperative period. The platelet count 
was determined preoperatively, day of surgery and every day 
until day 5 in the postoperative period. In-hospital mortality was 
defined as any death occurring within first 30 days after surgery. 
Aspirin and clopidogrel was discontinued 7 days before surgery 
and warfarin was stopped 5 days before operation.
Surgical Approach
A complete median sternotomy was performed and 
extracorporeal circulation (ECC) with moderate hypothermia 
(34°C) was employed in every patient. Antegrade cold blood 
cardioplegia was administered after application of cross clamp. 
The choice of prosthesis implanted was made by the surgeon. 
Perioperative transesophageal echocardiogram was performed 
routinely to confirm correct position of the valve, exclude any 
paravalvular leak and evaluate valve hemodynamics.
The Perimount Magna Ease valve was rinsed with normal 
saline for 3 minutes before implantation while Perceval valve 
does not require any rinsing before implantation. Perimount 
Magna Ease valves were intra implanted with interrupted or semi 
continuous 2/0 prolene sutures. 
The Perceval valve is a surgical bioprosthetic heart valve 
consists of glutaraldehyde-fixed bovine pericardium treated with 
homocysteic acid in order to remove the free aldehyde residues 
and prevent the calcification process. It is fixed in a metal cage 
made up of an alloy of nickel and titanium, known as nitinol. 
Three 4/0 polypropylene guiding sutures were passed at the 
nadir of the aortic annulus. An appropriately sized prosthesis 
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Table 1. Preoperative summary.
Perceval Perimount Chi-squared Test
Total  n=72 %  n=101 % P
Gender (male/female) 34/38 47/52% 69/31 69/31% 0.004
Cigarette smoking history 3 4% 11 11% 0.106
History of hypertension 57 79% 60 60% 0.01
Renal disease at time of surgery __ __ 1 1% 0.40
History of pulmonary disease (i.e: COPD, asthma) 16 22% 19 19% 0.61
History of neurological disease (i.e.: TIA, CVA) 12 17% 7 7% 0.05
Angina Status pre-surgery 39 54% 37 37% 0.03
0. No angina 33 46% 63 88%
1. No limitation of physical activity 16 22% 18 25%
2. Slight limitation of ordinary activity 11 15% 11 15%
3. Marked limitation of ordinary physical activity 10 14% 6 8%
4. Symptoms at rest or minimal activity 2 3% 2 3%
Dyspnoea status pre-surgery 65 90% 82 82% 0.13
1. No limitation of physical activity 7 10% 18 18%
2. Slight limitation of ordinary physical activity 23 32% 39 39%
3. Marked limitation of ordinary physical activity 41 57% 40 40%
4. Symptoms at rest or minimal activity 1 1% 3 3%
History of diabetes mellitus 13 18% 20 20% 0.75
Preoperative heart rhythm
0. Sinus rhythm 55 76% 84 87%
1. Atrial fibrillation/flutter 16 22% 12 12% 0.07
2. Complete heart block/pacing 1 1% __ __ 0.24
3. Other abnormal rhythm __ __ 1 1.0%
Ejection fraction category
1. Good (LVEF > 50%) 58 81% 84 84%
2. Fair (LVEF 30-50%) 12 17% 15 15% 0.77
3. Poor (LVEF < 30%) 2 3% 1 1% 0.38
COPD=chronic obstructive pulmonary disease; CVA=cerebrovascular accident; LVEF=left ventricular ejection fraction; TIA=transient 
ischemic attack 
Table 2. Preoperative summary (continued).
Perceval Perimount t-Test
Range Mean Median Range Mean Median
Two-Sample 
Assuming Unequal 
Variances
Age of patients at time of procedure 54-84 74 75 47-86 70 70.5 <0.001
Logistic EuroSCORE comparison 0.53-18.89 3.07 2.41 0-7.57 1.87 1.44 0.001
Height (cm) 140-185 164.1 163 138-185 167.3 169 0.029
Weight (kg) 40.3-158 82.2 80.1 50-181.6 84.90 81.1 0.387
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Table 4. Comparison of different sizes of valves in respect of drop in platelet count %.
Perceval valve Size  % Perimount Magna valve Size % P value
Small        66.11% 19-21 mm     48.36% 0.0001
Medium     56.28% 23 mm          43.25% 0.0003
Large         59.41% 25 mm          44.85% 0.0003
X large      56.89% 27-29 mm     39.3% 0.0005
Table 5. Haematology data.
Perceval valve
N=72
Perimount Magna
N=101
P
Maximum drop in platelet count: “which day” 
Mean 2.3
Median 2
Range 0-5
Mean 1.7
Median 2
Range 0-6
0.0005
Maximum drop in platelet count: “what %”
Mean 58.0%
Median 58.3%
Range 35-84%
Mean 44.3%
Median 45.0%
Range 14-64%
<0.0001
Blood transfusion: units
Mean 1.5
Median 0.5
Range 0-10
Mean 0.7
Median 0
Range 0-8
0.0091
Platelet transfusion: pool of platelets
Mean 0.3
Median 0
Range 0-4
Mean 0.1
Median 0
Range 0-2
0.0075
FFP Transfusion: units
Mean 0.2
Median 0
Range 0-4
Mean 0.1
Median 0
Range 0-3
0.21
Table 6. Haematology data (continued).
Patients having postoperative thrombocytopenia Perimount Magna valve Perceval valve P value
Moderate thrombocytopenia: <100 x 109 N=26 (26%) N=34 (41%) 0.008
Severe thrombocytopenia: <50 x 109 __ N=5 (6%)
Patients whose platelet level returned to preoperative level 
following surgery/did not return to preoperative
Perimount Magna valve 
N=44/57 (44/56%)
Perceval valve
N=20/56 (26/74%)
0.018
Table 3. Proportion of different valve sizes.
Perceval valve sizes N % Perimount Magna valve sizes N %
19 1 1
Small 8 11 21 20 11
Medium 20 28 23 42 42
Large 22 31 25 29 29
X large      22 31 27 10 18
29 __ __
Total 72 101
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significant difference in postoperative neurological dysfunction, 
renal impairment, atrial fibrillation, permanent pacemaker 
requirement or mortality could be observed.
DISCUSSION
Our retrospective study showed that there is a 
relationship between Perceval S valve implantation and severe 
thrombocytopenia. Severe thrombocytopenia in our study was 
Intraoperative and early postoperative variables are 
summarized in Tables 8 and 9. Cross clamp (range 23-76 min, 
mean 39 min vs. 24-133 min, mean 54 min; P=0.001)) and bypass 
time (range 25-119 min, mean 59 min vs. range 19-175 min, 
mean 71 min; P=0.001) were shorter in isolated Perceval valve 
group (Group A1) compared to isolated conventional valve 
group (Group B1).
Perceval valve patients spent more time in ICU compared 
to Perimount Magna patients (3.2 days vs. 1.9 days; P=0.005). No 
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Table 7. Absolute platelet count on preoperative, operative and postoperative days.
Platelet count on days Perimount Magna valve Perceval valve P value
Preoperative platelet count 244 239.8 =0.73
Operation day platelet count 158.6 144.6 =0.07
Postoperative day 1 platelet count 158.7 132.8 =0.0007
Postoperative day 2 platelet count 145.9 112.8 <0.0001
Postoperative day 3 platelet count 158.4 111.4 <0.0001
Postoperative day 4 platelet count 183.5 130.0 <0.0001
Postoperative day 5 platelet count 216.4 157.5 <0.0001
Postoperative day 6 platelet count 260.3 174.4 <0.0001
Postoperative day 7 platelet count 254.6 205.7 =0.23
Table 9. Intraoperative and early postoperative data (continued).
Perceval Perimount Chi-squared Test
Total n=72 % n=100 % P
Reoperation for bleeding, tamponade 2 2.78% 2 2.00% 0.738
Patient status at discharge (mortality) 1 1.39% __ 0.00% 0.237
Table 8. Intraoperative and early postoperative data.
Perceval Perimount
t-Test:
Two-Sample Assuming 
Unequal Variances
 Range Mean Median Range Mean Median P
Cumulative cross-clamp time (min)      23-76 39.2 38 24-133 54.1 48.5 <0.001
Cumulative bypass time              25-119 59.3 56.5 19-175 71.6 63.5 <0.001
Post operative blood loss @ 12 hours 15-2000 304 212.5 100-2000 359.7 300 0.197
ITU stay in days                 1-13 3.2 2 1-17 1.9 1 0.005
ITU=intensive care unit
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that patients undergoing AVR with the Carpentier-Edwards 
Perimount bioprosthesis or a Medtronic Freestyle stentless 
bioprosthesis had a lower minimum platelet count within the 
first five POD, compared to patients receiving ATS and St. Jude 
Medical mechanical prostheses.
In our study, the drop-in platelet count started to occur 
during the 3rd POD with very slow recovery toward the 7th to 10th 
POD. The lowest drop in platelet count was down to 22% of the 
preoperative baseline level and occurred in patients implanted 
with the Perceval valve. As shown in other studies, there were no 
other clinical consequences associated with thrombocytopenia 
that was transient but resulted in more transfusion requirements.
The bovine pericardium leaflets of both Perceval S valve 
and Mitroflow bioprosthesis are fixed in a process using 
gluteraldehyde. The Mitroflow prosthesis is stored in a solution of 
gluteraldehyde and needs rinsing before it is used. On the other 
side, the Perceval S prosthesis and Freedom Solo prosthesis 
are detoxified with homocysteic acid to eliminate any residual 
aldehyde and then stored in an aldehyde free solution; so, it does 
not require rinsing prior to use. Homocysteic acid can have a 
damaging effect on vessel endothelial cells and can precipitate 
platelet aggregation resulting in both thrombocytopenia and 
thrombotic complications[15]. These valves are carefully washed 
after detoxification with a homocysteic acid-free solution and 
then stored in jars filled with a homocysteic acid-free storage 
solution. Consequently, the residual amount of homocysteic 
acid, which could be transferred to the patient during the valve 
implantation, is negligible and the resulting concentration 
in blood is extremely low, so cannot be blamed for the 
postoperative thrombocytopenia. Moreover, the same solution 
is used for other bioprosthesis[16], without causing higher 
incidence of thrombocytopenia.
Mechanical stress and hemodynamic turbulence have also 
been proposed as a cause of thrombocytopenia after Freedom 
Solo prosthesis[10].
Small valve sizes have been described as causing 
some turbulence across the valve resulting in platelet 
activation or destruction, and consequently postoperative 
thrombocytopenia[7,9,14]. However, sutureless valves are well 
known for their superior hemodynamic performance and this 
hypothesis is quite unlikely.
Non-specific activation of platelets leading to diffuse 
consumption and thrombocytopenia after AVR with both 
mechanical and bioprosthetic aortic valves was suggested by 
Leguyader et al.[17]. Platelet activation could also result from valve 
manipulation or the presence of the metal stent.
The Perceval S valve has metal structure that serves as an 
anchoring system to the aortic valve, which could be the cause 
of turbulent flow, platelet rupture and mechanical structure. 
The metal stent may play a role in platelet activation and the 
possibility of paravalvular leaks may also trigger platelet activation 
and consumption. Moreover, the metal stents of these valves 
could interfere with the quality of images and could conceal or 
underestimate the degree of some paravalvular leaks[5].
Long CPB duration has been suggested by other studies to 
be associated with postoperative thrombocytopenia[14]. In our 
study the CPB durations were shorter in the sutureless group 
not associated with higher mortality and morbidity, and none of 
these deaths was related to severe thrombocytopenia.
Sánchez et al.[6] compared the incidence of thrombocytopenia 
after AVR with Perceval S Sutureless Bioprosthesis (n=27) 
and Mitroflow prostheses (n=50). The incidence of severe 
thrombocytopenia was significantly higher (P=0.046) in Perceval 
S patients than in Mitroflow patients. The platelet count 
recovered in all patients with severe thrombocytopenia.
The biological structure of the Perceval S valve and Freedom 
Solo stentless bioprosthesis are very similar[6].
Hilker et al.[7] compared the postoperative courses of platelet 
counts in patients having had AVR with stentless prostheses 
(Sorin Biomedica Freedom Solo [SOLO]) or stented prostheses 
(Carpentier Edwards Perimount [PM]). A higher occurrence of 
platelet levels below 100 Gpt/l between the second and the fifth 
postoperative day (POD) was found in the SOLO-group (71.9%) 
compared with the other biological substitute PM (36.6%).
Miceli et al.[8] evaluated the postoperative evolution of platelet 
count and function after AVR in 116 patients undergoing isolated 
stentless biological AVR with Freedom Solo and compared with 
206 patients who received stented biological valves. Freedom 
Solo implantation was associated with a higher incidence of 
thrombocytopenia compared with the control group (24.1% vs. 
4.4%, P<0.0001).
Piccardo et al.[9] also studied the incidence and clinical impact 
of thrombocytopenia in patients receiving AVR with Freedom 
Solo bioprosthesis and Carpentier-Edwards Perimount pericardial 
prosthesis. They reported that severe thrombocytopenia 
occurred in 25% and 3% of patients with Freedom Solo and 
Perimount bioprostheses, respectively (P<0.0001).
Yerebakan et al.[10] compared platelet counts within 2 weeks 
after implantation of either a stentless (Sorin Freedom Solo) or 
a stented (Sorin Mitroflow) bovine pericardial bioprosthesis. 
In the Mitroflow group, the mean platelet count moderately 
dropped to a minimum of 60% of the initial value on 3rd POD 
and fully recovered on 8th POD. In the Freedom Solo group, 
platelet loss was significantly more severe (minimum relative 
value 25% on 4th POD) with no recovery during follow-up. 
However, there were no other complications reported in 
association with thrombocytopenia related to the use of these 
Freedom Solo valves and the phenomenon was transient and 
resolved without clinical consequences or hemodynamic 
dysfunction[9,10].
Platelet count decrease has also been reported after 
percutaneous coronary intervention[11]. Gallet et al.[12] studied 
the effect of transcatheter (via femoral artery) aortic valve 
implantation (TAVI) on platelet count. They observed that platelet 
count systematically decreased after TAVI, with an average 
decrease of 34±15%, and a decrease in platelet count reported 
to be associated with in-hospital major adverse cardiovascular 
events and strongly influenced patient outcome. In the setting of 
TAVI procedures platelet activation can be caused by endothelial 
damage caused by prosthesis implantation, fibrinogen binding 
on metallic armatures, and shear stress modifications due to 
prosthesis implantation[13].
Van Straten et al.[14] compared thrombocytopenia after 
AVR with mechanical and biological valves. They concluded 
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than the sutured one so it cannot be responsible for post-
operative thrombocytopenia.
Severe thrombocytopenia is a common complication in 
patients who undergo cardiac surgery with ECC. It occurs as result 
of structural changes and activation of platelets, hemodilution, 
platelet aggregation and bleeding[18].
Limitations
The main limitation of our study is due to its observational, 
non-randomized and retrospective characteristics. Heparin 
induced thrombocytopenia was not investigated as a 
possible cause of thrombocytopenia, as it appears after the 5th 
postoperative day[18].
CONCLUSION
It seems to be an association between sutureless Perceval 
valve and severe thrombocytopenia, although it does not affect 
patient’s mortality and morbidity. These patients had also higher 
rate of blood and platelets transfusion. A prospective randomised 
trial is needed to confirm our findings.  
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